Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals
NCT ID: NCT04340349
Last Updated: 2021-06-29
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
EARLY_PHASE1
Total Enrollment
214 participants
Study Classification
INTERVENTIONAL
Study Start Date
2021-02-01
Study Completion Date
2021-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will investigate the security and efficacy of a daily low dose of hydroxychloroquine and Bromhexine, in preventing the development of the disease from COVID-19 in Health Care Workers at a National Institute of Health In Mexico City.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19
NCT04347239
Coronavirus Disease 2019
COMPLETED
PHASE2
Bronchopulmonary PK of AT-527 (R07496998)
NCT04877769
Healthy Volunteer Study
COMPLETED
PHASE1
Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).
NCT05010876
Covid19
COMPLETED
PHASE2
Intravenous L-Citrulline Influence on the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19
NCT04570384
Acute Hypoxemic Respiratory Failure
COMPLETED
PHASE2
ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19
NCT04604184
COVID-19
TERMINATED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will combine two drugs (hydroxychloroquine and Bromhexine) to see if hydroxychloroquine is better in combination with Bromhexine in preventing the development of the disease from COVID-19 in Health Care Workers at a National Institute of Health In Mexico City. Hydroxychloroquine will be used in a low dose (200 mg every 24 hrs). Bromhexine will be 8mg every 8 hrs. The study groups will be the following: 1) HCQ 200mg/d + BHH placebo 2) HCQ placebo plus BHH placebo
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Hydroxychloroquine
Antimalarials
Enzyme Inhibitors
Antirheumatic Agents
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Parallel Assignment
Primary Study Purpose
PREVENTION
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
DOUBLE BLINDED
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental: Hydroxychloroquine plus Bromhexine
200 mg of Hydroxychloroquine daily for 2 months 8 mg of Bromhexine every 8 hrs for 2 months
Group Type
EXPERIMENTAL
Hydroxychloroquine Sulfate
Intervention Type
DRUG
A daily low dose of Hydroxychloroquine Sulfate. Increase the endosomal pH and inhibits of ACE2 glycosylation receptor.
Bromhexine 8 MG
Intervention Type
DRUG
TMPRSS2 blocker
Hydroxychloroquine plus Bromhexine
200 mg of Hydroxycholoroquine daily for 2 months 8 mg of Bromhexine every 8 hrs for 2 months
Group Type
PLACEBO_COMPARATOR
Hydroxychloroquine Sulfate
Intervention Type
DRUG
A daily low dose of Hydroxychloroquine Sulfate. Increase the endosomal pH and inhibits of ACE2 glycosylation receptor.
Bromhexine 8 MG
Intervention Type
DRUG
TMPRSS2 blocker
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hydroxychloroquine Sulfate
A daily low dose of Hydroxychloroquine Sulfate. Increase the endosomal pH and inhibits of ACE2 glycosylation receptor.
Intervention Type
DRUG
Bromhexine 8 MG
TMPRSS2 blocker
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Evoquin
Bisolvon
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Health personnel working at INR LGII or INCMNSZ who wish to participate in the study and sign the informed consent.
* Over 18 and under 60 years of age, both genders.
* Contacting with suspected or confirmed SARS-CoV-2 infection.
* Normal electrocardiogram.
* Over 18 and under 60 years of age, both genders.
* Contacting with suspected or confirmed SARS-CoV-2 infection.
* Normal electrocardiogram.
Exclusion Criteria
* Positive quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) test for SARS-CoV-2 at the time of inclusion.
* Panel of IgG or IgM antibodies positive for SARS-CoV-2 at the time of inclusion.
* Development of respiratory symptoms suspicious of SARS-CoV-2 infection during the first 7 days after treatment is initiated, confirmed by qRT-PCR and IgG or IgM antibodies postiver for SARS-CoV-2.
* History of allergies to any hydroxychloroquine or bromhexine related compound or medication.
* Use of immunosuppressors for any reason.
* History of bone marrow transplant.
* Known glucose-6-phosphate dehydrogenase deficiency.
* Chronic kidney disease or glomerular filtration \<20ml/min.
* Use of other drugs with reported pharmacological interactions (i.e., digitalis, flecainide, amiodarone, procainamide, or propafenone).
* History of long QT syndrome.
* Electrocardiogram with QTc\>500 msec.
* Pregnant or breastfeeding personnel.
* Epilepsy.
* Known liver disease.
* Personnel who have received the Covid-19 vaccine
Elimination criteria
* Personnel who decide to leave the study for any reason not related to adverse events.
* Personnel with incomplete information on the primary outcome (qRT-PCR for SARS-CoV-2).
* Personnel who are relocated to work in another institution.
* Personnel who do not wish to participate in the study
* Panel of IgG or IgM antibodies positive for SARS-CoV-2 at the time of inclusion.
* Development of respiratory symptoms suspicious of SARS-CoV-2 infection during the first 7 days after treatment is initiated, confirmed by qRT-PCR and IgG or IgM antibodies postiver for SARS-CoV-2.
* History of allergies to any hydroxychloroquine or bromhexine related compound or medication.
* Use of immunosuppressors for any reason.
* History of bone marrow transplant.
* Known glucose-6-phosphate dehydrogenase deficiency.
* Chronic kidney disease or glomerular filtration \<20ml/min.
* Use of other drugs with reported pharmacological interactions (i.e., digitalis, flecainide, amiodarone, procainamide, or propafenone).
* History of long QT syndrome.
* Electrocardiogram with QTc\>500 msec.
* Pregnant or breastfeeding personnel.
* Epilepsy.
* Known liver disease.
* Personnel who have received the Covid-19 vaccine
Elimination criteria
* Personnel who decide to leave the study for any reason not related to adverse events.
* Personnel with incomplete information on the primary outcome (qRT-PCR for SARS-CoV-2).
* Personnel who are relocated to work in another institution.
* Personnel who do not wish to participate in the study
Minimum Eligible Age
18 Years
Maximum Eligible Age
59 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Instituto Nacional de Rehabilitacion
OTHER_GOV
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Julio Granados Montiel
Principal Investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Julio Granados-Montiel, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Instituto Nacional de Rehabilitacion
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institute of Rehabilitation, Luis Guillermo Ibarra Ibarra
Mexico City, Mexico City, Mexico
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Mexico
References
Explore related publications, articles, or registry entries linked to this study.
Pal M, Berhanu G, Desalegn C, Kandi V. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update. Cureus. 2020 Mar 26;12(3):e7423. doi: 10.7759/cureus.7423.
Reference Type
BACKGROUND
Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020 Apr 11;395(10231):1225-1228. doi: 10.1016/S0140-6736(20)30627-9. Epub 2020 Mar 13.
Reference Type
BACKGROUND
Luzzi GA, Peto TE. Adverse effects of antimalarials. An update. Drug Saf. 1993 Apr;8(4):295-311. doi: 10.2165/00002018-199308040-00004.
Reference Type
BACKGROUND
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Mar 16;14(1):72-73. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.
Reference Type
BACKGROUND
Dutta D, Sharma M, Sharma R. Short-term Hydroxychloroquine in COVID-19 Infection in People With or Without Metabolic Syndrome - Clearing Safety Issues and Good Clinical Practice. Eur Endocrinol. 2020 Oct;16(2):109-112. doi: 10.17925/EE.2020.16.2.109. Epub 2020 Oct 6.
Reference Type
BACKGROUND
Paiardini M, Muller-Trutwin M. HIV-associated chronic immune activation. Immunol Rev. 2013 Jul;254(1):78-101. doi: 10.1111/imr.12079.
Reference Type
BACKGROUND
Chang R, Sun WZ. Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges. Drug Discov Today. 2020 Oct;25(10):1786-1792. doi: 10.1016/j.drudis.2020.06.030. Epub 2020 Jul 3.
Reference Type
BACKGROUND
Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. CMAJ. 2020 Apr 27;192(17):E450-E453. doi: 10.1503/cmaj.200528. Epub 2020 Apr 8. No abstract available.
Reference Type
BACKGROUND
Zanasi A, Mazzolini M, Kantar A. A reappraisal of the mucoactive activity and clinical efficacy of bromhexine. Multidiscip Respir Med. 2017 Mar 20;12:7. doi: 10.1186/s40248-017-0088-1. eCollection 2017.
Reference Type
BACKGROUND
Depfenhart M, de Villiers D, Lemperle G, Meyer M, Di Somma S. Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy? Intern Emerg Med. 2020 Aug;15(5):801-812. doi: 10.1007/s11739-020-02383-3. Epub 2020 May 26.
Reference Type
BACKGROUND
Ravi N, Cortade DL, Ng E, Wang SX. Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape. Biosens Bioelectron. 2020 Oct 1;165:112454. doi: 10.1016/j.bios.2020.112454. Epub 2020 Jul 18.
Reference Type
BACKGROUND
Lai C, Yu R, Wang M, Xian W, Zhao X, Tang Q, Chen R, Zhou X, Li X, Li Z, Li Z, Deng G, Wang F. Shorter incubation period is associated with severe disease progression in patients with COVID-19. Virulence. 2020 Dec;11(1):1443-1452. doi: 10.1080/21505594.2020.1836894.
Reference Type
RESULT
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
Reference Type
RESULT
Li C, Ji F, Wang L, Wang L, Hao J, Dai M, Liu Y, Pan X, Fu J, Li L, Yang G, Yang J, Yan X, Gu B. Asymptomatic and Human-to-Human Transmission of SARS-CoV-2 in a 2-Family Cluster, Xuzhou, China. Emerg Infect Dis. 2020 Jul;26(7):1626-1628. doi: 10.3201/eid2607.200718. Epub 2020 Jun 21.
Reference Type
RESULT
Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, Li T, Chen Q. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020 Feb 24;12(1):8. doi: 10.1038/s41368-020-0074-x.
Reference Type
RESULT
Levy A, Yagil Y, Bursztyn M, Barkalifa R, Scharf S, Yagil C. ACE2 expression and activity are enhanced during pregnancy. Am J Physiol Regul Integr Comp Physiol. 2008 Dec;295(6):R1953-61. doi: 10.1152/ajpregu.90592.2008. Epub 2008 Oct 22.
Reference Type
RESULT
Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem Neurosci. 2020 Apr 1;11(7):995-998. doi: 10.1021/acschemneuro.0c00122. Epub 2020 Mar 13.
Reference Type
RESULT
Zhan M, Qin Y, Xue X, Zhu S. Death from Covid-19 of 23 Health Care Workers in China. N Engl J Med. 2020 Jun 4;382(23):2267-2268. doi: 10.1056/NEJMc2005696. Epub 2020 Apr 15. No abstract available.
Reference Type
RESULT
Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648. No abstract available.
Reference Type
RESULT
Liu Q, Bi G, Chen G, Guo X, Tu S, Tong X, Xu M, Liu M, Wang B, Jiang H, Wang J, Li H, Wang K, Liu D, Song C. Time-Dependent Distribution of Hydroxychloroquine in Cynomolgus Macaques Using Population Pharmacokinetic Modeling Method. Front Pharmacol. 2021 Jan 14;11:602880. doi: 10.3389/fphar.2020.602880. eCollection 2020.
Reference Type
RESULT
Wang LF, Lin YS, Huang NC, Yu CY, Tsai WL, Chen JJ, Kubota T, Matsuoka M, Chen SR, Yang CS, Lu RW, Lin YL, Chang TH. Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery. J Interferon Cytokine Res. 2015 Mar;35(3):143-56. doi: 10.1089/jir.2014.0038. Epub 2014 Oct 16.
Reference Type
RESULT
Helal GK, Gad MA, Abd-Ellah MF, Eid MS. Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients. J Med Virol. 2016 Dec;88(12):2170-2178. doi: 10.1002/jmv.24575. Epub 2016 May 25.
Reference Type
RESULT
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4. No abstract available.
Reference Type
RESULT
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
Reference Type
RESULT
Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, Zhang P, Liu X, Gao G, Liu F, Jiang Y, Cheng X, Zhu C, Xia Y. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020 Dec;9(1):1123-1130. doi: 10.1080/22221751.2020.1770129.
Reference Type
RESULT
Chude CI, Amaravadi RK. Targeting Autophagy in Cancer: Update on Clinical Trials and Novel Inhibitors. Int J Mol Sci. 2017 Jun 16;18(6):1279. doi: 10.3390/ijms18061279.
Reference Type
RESULT
Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, Labella A, Manson DK, Kubin C, Barr RG, Sobieszczyk ME, Schluger NW. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020 Jun 18;382(25):2411-2418. doi: 10.1056/NEJMoa2012410. Epub 2020 May 7.
Reference Type
RESULT
Zahr N, Urien S, Llopis B, Pourcher V, Paccoud O, Bleibtreu A, Mayaux J, Gandjbakhch E, Hekimian G, Combes A, Benveniste O, Saadoun D, Allenbach Y, Pinna B, Cacoub P, Funck-Brentano C, Salem JE. Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. Therapie. 2021 Jul-Aug;76(4):285-295. doi: 10.1016/j.therap.2021.01.056. Epub 2021 Jan 28.
Reference Type
RESULT
Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Muller MA, Drosten C, Pohlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
Reference Type
RESULT
Mareev VY, Orlova YA, Pavlikova EP, Matskeplishvili ST, Akopyan ZA, Plisyk AG, Seredenina EM, Asratyan DA, Potapenko AV, Malakhov PS, Samokhodskaya LM, Mershina EA, Sinitsyn VE, Bulanova MM, Fuks AA, Mareev YV, Begrambekova YL, Kamalov AA. [Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial "BromhexIne and Spironolactone for Coronsmall a, CyrillicvirUs Infection requiring hospiTalization (BISCUIT)"]. Kardiologiia. 2020 Sep 7;60(8):4-15. doi: 10.18087/cardio.2020.8.n1307. Russian.
Reference Type
RESULT
Granados-Montiel J, Hazan-Lasri E, Franco-Cendejas R, Chavez-Heres T, Silva-Bermudez P, Aguilar-Gaytan R, Manzano-Leon N, Mendez-Maldonado K, Alvarez-Arce A, Martinez-Portilla RJ. New prophylaxis regimen for SARS-CoV-2 infection in health professionals with low doses of hydroxychloroquine and bromhexine: a randomised, double-blind placebo clinical trial (ELEVATE Trial). BMJ Open. 2021 Aug 3;11(8):e045190. doi: 10.1136/bmjopen-2020-045190.
Reference Type
DERIVED
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Related Links
Access external resources that provide additional context or updates about the study.
https://covid19.who.int/region/amro/country/mx
Dashboard Mexico 2021
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
25/20
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise
NCT04472494
TERMINATED
PHASE2
Safety and Pharmacokinetics of FBR-002 for the Treatment of Patients Hospitalized With COVID-19 in Need of Supplemental Oxygen and at Risk of Severe Outcome
NCT05279352
UNKNOWN
PHASE2
A Clinical Study of RSS0343 in Healthy Subjects
NCT07289464
RECRUITING
PHASE1
Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients
NCT04472728
TERMINATED
PHASE2/PHASE3
Clinical Trial to Assess the Efficacy and Safety of Inhaled AQ001S in the Management of Acute COVID-19 Symptoms
NCT05000346
TERMINATED
PHASE2
Safety and Pharmacokinetic (PK) Study to Assess Bronchopulmonary Disposition of IV Eravacycline (TP-434) in Healthy Men and Women
NCT01989949
COMPLETED
PHASE1
A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia
NCT04659122
TERMINATED
PHASE1
Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.
NCT04348383
COMPLETED
PHASE2
A Study to Evaluate the Efficacy of EQ-778 on Upper Respiratory Tract Health Status in Healthy Adults
NCT05835375
RECRUITING
NA
Effect of Inhaled Hydroxy Gas on Long COVID Symptoms
NCT06159296
RECRUITING
NA
Efficacy of Breathox Device Inhalation Therapy in the Treatment of Acute Symptoms Associated With COVID-19 and in the Prevention of the Use of Health Resources
NCT05196581
COMPLETED
PHASE2
A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure
NCT04574869
WITHDRAWN
PHASE1
Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation
NCT04901689
SUSPENDED
PHASE3
The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)
NCT04389671
COMPLETED
PHASE2
Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175
NCT05628740
COMPLETED
PHASE1
Influence of IQPAS-119 on Post-Marathon Susceptibility to Infections and Others
NCT02873910
COMPLETED
NA
Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19
NCT06383819
COMPLETED
PHASE3
INB03 for the Treatment of Pulmonary Complications From COVID-19
NCT04370236
TERMINATED
PHASE2/PHASE3
Study to Evaluate the Efficacy and Safety of EG-009A Compared to DEX in Patients With COVID-19 Pneumonia
NCT04561180
WITHDRAWN
PHASE2
Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Exosomes in Treating Chronic Cough After COVID-19
NCT05808400
UNKNOWN
EARLY_PHASE1
Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease
NCT05258682
UNKNOWN
PHASE1/PHASE2
Tocilizumab Treatment in Patients With COVID-19
NCT04363853
ACTIVE_NOT_RECRUITING
PHASE2
Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis
NCT00930982
COMPLETED
PHASE2
To Evaluate the Safety and Efficacy of Inhaled CT-P63 and CT-P66 Combination Therapy in Symptomatic Patients With COVID-19 Not Requiring Supplemental Oxygen
NCT05224856
WITHDRAWN
PHASE3
The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
NCT04313023
COMPLETED
PHASE2